Dexcom (DXCM) | Stock Overview & Key Data
Dexcom Performance Comparison
Stock Range
Today's Range
Low: $64.67
High: $66.82
on October 2, 2025
52 Week Range
Low: $57.52
High: $93.25
on April 4, 2025
on February 18, 2025
All-Time High: $164.86 on November 15, 2021
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$26.2B
EPS
1.41
P/E Ratio (TTM)
47.39
Forward P/E
32.91
P/B Ratio
10.18
PEG Ratio
1.71
Div. Yield
N/A
ROE
22.83%
Beta
1.487
Debt to Equity
100.24
Financial Highlights
Profitability
Gross Margin
59.53%
Operating Margin
18.37%
Profit Margin
13.29%
Returns and Earnings
Return on Assets (TTM)
6.08%
Return on Equity (TTM)
22.83%
EBITDA
$1.0B
Net Income (TTM)
$571.5M
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$11.01
Quarterly Revenue Growth (YoY)
15.20%
Quarterly Earnings Growth (YoY)
25.30%
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Dexcom DXCM | 26.16B Large-cap | -2.72% | -10.58% | -20.51% | -2.49% | -15.36% | -2.45% | -34.95% | -31.15% |
| Abbott Laboratories ABT | 231.60B Mega-cap | -0.24% | 1.16% | -0.84% | 0.80% | 17.23% | 18.07% | 30.65% | 21.29% |
| Boston Scientific BSX | 142.83B Large-cap | -1.96% | -9.79% | -7.15% | -3.83% | 7.65% | 13.82% | 142.00% | 133.88% |
| Stryker SYK | 139.22B Large-cap | -0.59% | -6.04% | -6.49% | -2.93% | 2.14% | 4.32% | 75.71% | 64.36% |
| Medtronic plc MDT | 121.93B Large-cap | 1.25% | 2.30% | 8.16% | 7.45% | 19.02% | 8.18% | 15.85% | -12.15% |
| Edwards Lifesciences EW | 45.70B Large-cap | 1.83% | -6.26% | -0.48% | 6.38% | 5.59% | 17.04% | -9.00% | -8.64% |
Ownership & Short Interest
Insider Ownership
0.42%
Institutional Ownership
97.43%
Shares Short
13M
Short Ratio
3.18
Short % of Shares Outstanding
4.30%
Average 10-Day Volume
8M
Average 90-Day Volume
6M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is DXCM's 52-week high and low?
- In the last 52 weeks, Dexcom reached a high of $93.25 (on February 18, 2025) and a low of $57.52 (on April 4, 2025).
- What is the market cap and P/E ratio for DXCM?
- Curious about Dexcom's size and valuation? Its market capitalization stands at 26.16B. When it comes to valuation, the P/E ratio (trailing twelve months) is 47.39, and the forward P/E (looking ahead) is 32.91.
- Does DXCM pay dividends? If so, what's the yield?
- As for dividends, Dexcom isn't currently offering a significant yield, or that specific data isn't available right now.
- Who are Dexcom's main competitors or similar companies to consider before investing?
When looking at Dexcom, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Abbott Laboratories
ABT231.60B Healthcare Medical Devices 18.07% 30.65% Boston Scientific
BSX142.83B Healthcare Medical Devices 13.82% 142.00% Stryker
SYK139.22B Healthcare Medical Devices 4.32% 75.71% Medtronic plc
MDT121.93B Healthcare Medical Devices 8.18% 15.85% Edwards Lifesciences
EW45.70B Healthcare Medical Devices 17.04% -9.00% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Dexcom Inc.? (e.g., ROE, Debt/Equity)
- To get a sense of Dexcom's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 22.83%, the Debt to Equity ratio from the most recent quarter is 100.24, and its Gross Profit Margin stands at 59.53%.
- What is the recent revenue and earnings growth for DXCM?
- Looking at Dexcom's growth, its revenue over the trailing twelve months (TTM) was $4B. Compared to the same quarter last year (YoY), quarterly revenue grew by 15.20%, and quarterly earnings saw a YoY growth of 25.30%.
- How much of DXCM stock is held by insiders and institutions?
- Wondering who owns Dexcom stock? Company insiders (like executives and directors) hold about 0.42% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 97.43%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.